SCHEMBL1827462

SCHEMBL1827462

CC(C)CCCCCCC[C]=O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
KDM4C Q9H3R0 2/20 0.33
TRPV1 Q8NER1 1/20 0.33
KDM4A O75164 1/20 0.33
PHF8 Q9UPP1 1/20 0.33
KDM2A Q9Y2K7 1/20 0.33
TRPA1 O75762 1/20 0.33
BLM P54132 1/20 0.32
HIF1A Q16665 1/20 0.32
EPAS1 Q99814 1/20 0.32
MEN1 O00255 1/20 0.30
USP2 O75604 1/20 0.30
ALDH1A1 P00352 1/20 0.30
TP53 P04637 1/20 0.30
CYP3A4 P08684 1/20 0.30
MAPT P10636 1/20 0.30
MAPK1 P28482 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1985823 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL2175496 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL2176899 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL2177991 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL2174526 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL132521 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL2173439 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL536857 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL443449 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL294141 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10294275-B2 Site-selective functionalization of glycopeptide antibiotics YALE UNIVERSITY (US) 2019-05-21 US claimed
US-20160039881-A1 SITE-SELECTIVE FUNCTIONALIZATION OF GLYCOPEPTIDE ANTIBIOTICS YALE UNIVERSITY (US) 2016-02-11 US claimed
WO-2014160250-A9 SITE-SELECTIVE FUNCTIONALIZATION OF GLYCOPEPTIDE ANTIBIOTICS YALE UNIVERSITY (US) 2015-12-17 WO claimed
WO-2014160250-A2 SITE-SELECTIVE FUNCTIONALIZATION OF GLYCOPEPTIDE ANTIBIOTICS YALE UNIVERSITY (US) 2014-10-02 WO claimed
CN-101792474-B Novel AzalomycinF microlide compounds and preparation method thereof and application thereof INST TROPICAL BIOSCIENCE & BIOTECHNOLOGY CATAS 2013-01-02 CN claimed
CN-101792474-A Novel AzalomycinF microlide compounds and preparation method thereof and application thereof INST TROPICAL BIOSCIENCE & BIOTECHNOLOGY CATAS 2010-08-04 CN claimed
US-5936074-A REACTING TEICOPLANIN WITH ECHINOCANDIN BETA DEACYLASE, THEN FORMING SALT AND/OR DEPROTECTING AMINO GROUP; BACTERICIDES AGAINST GRAM-POSITIVE BACTERIA ELI LILLY AND COMPANY (US) 1999-08-10 US claimed
US-5869449-A IMPROVED ANTIBACTERIAL ACTIVITY AGAINST SOME CLINICAL ISOLATES OF STAPHYLOCOCCI SOMEWHAT RESISTANT TO TEICOPLANIN. GRUPPO LEPETIT S.P.A. (IT) 1999-02-09 US claimed
EP-0873996-A1 Process of deacylation of teicoplanin and product thereby obtained ELI LILLY AND COMPANY (US) 1998-10-28 EP claimed
WO-1998046580-A1 DEACYLATION PROCESS AND PRODUCT ELI LILLY AND COMPANY (US) 1998-10-22 WO claimed
EP-0340245-B1 SUBSTITUTED ALKYLAMIDES OF TEICOPLANIN COMPOUNDS GRUPPO LEPETIT S.p.A. (IT) 1992-08-19 EP claimed
WO-1992010516-A1 38-DECARBOXY-38-HYDROXYMETHYL DERIVATIVES OF TEICOPLANIN ANTIBIOTICS, AND A PROCESS FOR PREPARING THEM GRUPPO LEPETIT S.P.A. (IT) 1992-06-25 WO claimed
EP-0465481-A1 NEW SUBSTITUTED ALKYLAMIDE DERIVATIVES OF TEICOPLANIN. LEPETIT SPA (IT) 1992-01-15 EP claimed
EP-0460448-A2 Use of C63-amide derivatives of 34-de(acetylglucosaminyl)-34-deoxy-teicoplanin against bacteria resistant to glycopeptide antibiotics GRUPPO LEPETIT S.p.A. (IT) 1991-12-11 EP claimed
WO-1990011300-A1 NEW SUBSTITUTED ALKYLAMIDE DERIVATIVES OF TEICOPLANIN GRUPPO LEPETIT S.P.A. (IT) 1990-10-04 WO claimed
CN-1043941-A 34-takes off the C63 amide derivatives of (N-acetyl glucosamine amido)-34-deoxidation-teicoplanins LEPETIT SPA (IT) 1990-07-18 CN claimed
EP-0376041-A2 C63-Amide derivatives of 34-de(acetylglucosaminyl)-34-deoxy-teicoplanins GRUPPO LEPETIT S.p.A. (IT) 1990-07-04 EP claimed
EP-0340245-A1 SUBSTITUTED ALKYLAMIDES OF TEICOPLANIN COMPOUNDS. LEPETIT SPA (IT) 1989-11-08 EP claimed
CN-88101000-A The alkylamide of the replacement of teicoplanin compounds 1988-09-14 CN claimed
WO-1988006600-A1 SUBSTITUTED ALKYLAMIDES OF TEICOPLANIN COMPOUNDS GRUPPO LEPETIT S.P.A. (IT) 1988-09-07 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039881-A1 SITE-SELECTIVE FUNCTIONALIZATION OF GLYCOPEPTIDE ANTIBIOTICS CUTA, VIP, GNE LMNA 3000/4885KDM4C 4198/4885TRPV1 1147/4885
US-10294275-B2 Site-selective functionalization of glycopeptide antibiotics CUTA, VIP, GNE LMNA 3000/4885KDM4C 4198/4885TRPV1 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.